Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small cell lung cancer xenograft mouse model

Acta Pharmacologica Sinica

Volumn 34, Issue 11, 2013, Pages 1427-1436

  Wu, Qiong ^b   Li, Meng Yao ^b   Li, Han Qing ^b   Deng, Chen Hui ^b   Li, Liang ^a,b   Zhou, Tian Yan ^a,b   Lu, Wei ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Anticancer drug; Epidermal growth factor receptor; Erlotinib; Human tumor xenograft mouse model; Non small cell lung cancer; Pharmacokinetic pharmacodynamic modeling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TANDEM MASS SPECTROMETRY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84887356533     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2013.101     Document Type: Article

References (32)

1. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.
2. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82: 241-50. (Pubitemid 29255919)
3. Baselga J. Monoclonal antibodies directed at growth factor receptors. Ann Oncol 2000; 11: 187-90.
4. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20: 2240-50. (Pubitemid 34441651)
5. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19: 3267-79. (Pubitemid 32591445)
6. Thomas F, Rochaix P, White-Koning M, Hennebelle I, Sarini J, Benlyazid A, et al. Population pharmacokinetics of erlotinib and its pharmacokinetic/ pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur J Cancer 2009; 45: 2316-23.
7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-32. (Pubitemid 41058344)
8. Yarden Y. The EGFR family and its ligands in human cancer signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37: S3-8. (Pubitemid 32938123)
9. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85. (Pubitemid 41095117)
10. Jackson RC. Pharmacodynamic modelling of biomarker data in oncology. ISRN Pharmacol 2012; 2012: 590626.
11. Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 2007; 96: 213-68.
12. Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006; 12: 7180-6. (Pubitemid 44974520)
13. Yamazaki S, Skaptason J, Romero D, Lee JH, Zou HY, Christensen JG, et al. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 2008; 36: 1267-74. (Pubitemid 351929310)
14. Lee L, Niu H, Rueger R, Igawa Y, Deutsch J, Ishii N, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker. Clin Cancer Res 2009; 15: 7368-74.
15. Salphati L, Pang J, Plise EG, Chou B, Halladay JS, Olivero AG, et al. Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human. Xenobiotica 2011; 41: 1088-99.
16. Luo FR, Yang Z, Dong H, Camuso A, McGlinchey K, Fager K, et al. Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model. Clin Cancer Res 2005; 11: 5558-65. (Pubitemid 41060833)
17. Li M, Li H, Cheng X, Wang X, Li L, Zhou T, et al. Preclinical Pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine. Pharm Res 2013; 30: 1400-8.
18. Li HQ, Chen Y, Li ZQ, Deng CH, Li L, Bi SS, et al. A high performance liquid chromatography method for the quantitative determination of erlotinib in the plasma of tumor bearing BALB/c nude mice and its application in a pharmacokinetic study. J Chin Pharmaceut Sci 2011; 20: 245-52.
19. Aquino G, Pannone G, Santoro A, Liguori G, Franco R, Serpico R, et al. pEGFR-Tyr 845 expression as prognostic factors in oral squamous cell carcinoma: a tissue-microarray study with clinic-pathological correlations. Cancer Biol Ther 2012; 13: 967-77.
20. Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, et al. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 2004; 64: 1094-101. (Pubitemid 38176915)
21. Li J, Zhao M, He P, Hidalgo M, Baker SD. Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 2007; 13: 3731-7. (Pubitemid 46955138)
22. Jusko WJ, Ko HC. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994; 56: 406-19. (Pubitemid 24339087)
23. Xu L, Eiseman JL, Egorin MJ, D'Argenio DZ. Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17- demethoxygeldanamycin and its active metabolite in tumor-bearing mice. J Pharmacokinet Pharmacodyn 2003; 30: 185-219. (Pubitemid 37176045)
24. Norton L, Simon R. Growth curve of an experimental solid tumor following radiotherapy. J Natl Cancer Inst 1977; 58: 1735-41. (Pubitemid 8118751)
25. Bissery MC, Vrignaud P, Lavelle F, Chabot GG. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs 1996; 7: 437-60. (Pubitemid 26249198)
26. Koch G, Walz A, Lahu G, Schropp J. Modeling of tumor growth and anticancer effects of combination therapy. J Pharmacokinet Pharmacodyn 2009; 36: 179-97.
27. Yamazaki S, Nguyen L, Vekich S, Shen Z, Yin MJ, Mehta PP, et al. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available heat shock protein 90 inhibitor in a human tumor xenograft mouse model. J Pharmacol Exp Ther 2011; 338: 964-73.
28. Mager DE, Jusko WJ. Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther 2001; 70: 210-6. (Pubitemid 32868484)
29. Uchida H, Mamo DC, Pollock BG, Suzuki T, Tsunoda K, Watanabe K, et al. Predicting plasma concentration of risperidone associated with dosage change: a population pharmacokinetic study. Ther Drug Monit 2012; 34: 182-7.
30. Ciardiello F, Tortora G. Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003; 39: 1348-54. (Pubitemid 36773776)
31. Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 1993; 21: 457-78. (Pubitemid 24025269)
32. Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004; 22: 3080-90. (Pubitemid 41103720)